🇺🇸 FDA
Pipeline program

5% Bisphosphocin Topical Gel

LLA-Nu-3-CLIN002

Phase 2 small_molecule terminated

Quick answer

5% Bisphosphocin Topical Gel for Chronic Diabetic Foot Ulcers is a Phase 2 program (small_molecule) at Lakewood-Amedex Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Lakewood-Amedex Biotherapeutics
Indication
Chronic Diabetic Foot Ulcers
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials